Bright Minds Biosciences Inc. (DRUG) Financial Statements
Bright Minds Biosciences Inc. (DRUG) reported trailing twelve-month revenue of $1.5M (up 4942.5% year on year) and net income of -$12.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · read by EquiReason
DRUGBright Minds Biosciences Inc.Follow DRUG — free
—
Price chart with a free account
- Market cap
- 237.4M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Aug, in -68 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters.
| Line | FY2024 Sep 24 | FY2025 Sep 25 | TTM | Trend |
|---|---|---|---|---|
| Revenue | 0.0 | 1.5 | — | |
| Research & development | 1.2 | 11.1 | — | |
| Pre-tax income | -2.8 | -12.2 | — | |
| Income tax | 0.0 | — | — | |
| Net income | -2.8 | -12.2 | — | |
| Diluted EPS ($) | -0.65 | — | — | |
| Diluted shares (mn) | 4.3 | — | — |
USD millions · SEC XBRL
Bright Minds Biosciences Inc. — questions
- What is Bright Minds Biosciences Inc.'s revenue?
- $1.5M over the twelve months to the latest filing, up 4942.5% year on year, from its 10-Q and 10-K filings.
- What is Bright Minds Biosciences Inc.'s net income?
- -$12.2M over the twelve months to .
Every figure on this page comes from Bright Minds Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.